1. Home
  2. ZLAB vs WLYB Comparison

ZLAB vs WLYB Comparison

Compare ZLAB & WLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

SELL

Current Price

$22.66

Market Cap

2.6B

Sector

Health Care

ML Signal

SELL

Logo John Wiley & Sons Inc.

WLYB

John Wiley & Sons Inc.

SELL

Current Price

$50.82

Market Cap

2.6B

ML Signal

SELL

Company Overview

Basic Information
Metric
ZLAB
WLYB
Founded
2013
1807
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Books
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
ZLAB
WLYB
Price
$22.66
$50.82
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $33.48
N/A
AVG Volume (30 Days)
★ 955.0K
249.0
Earning Date
11-05-2026
12-03-2026
Dividend Yield
N/A
★ 2.81%
EPS Growth
38.46
★ 171.90
EPS
★ N/A
N/A
Revenue
$460,156,000.00
★ $1,796,103,000.00
Revenue This Year
N/A
$4.68
Revenue Next Year
$26.74
$3.13
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 15.33
4.51
52 Week Low
$15.96
$29.16
52 Week High
$27.50
$55.51

Technical Indicators

Market Signals
Indicator
ZLAB
WLYB
Relative Strength Index (RSI) 45.61 48.99
Support Level $21.86 $50.55
Resistance Level $26.64 $54.08
Average True Range (ATR) 1.14 0.13
MACD -0.12 0.11
Stochastic Oscillator 33.86 44.51

Price Performance

Historical Comparison
ZLAB
WLYB

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About WLYB John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning, which includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

Share on Social Networks: